Литература
1. Горобцова В.В., Ковалев А.А. Рак шейки матки: актуальность проблемы, принципы лечения // Главный врач Юга России. 2016. № 1 (48). С. 63-66.
2. Дубровина С.О. Первичная и вторичная профилактика рака шейки матки (по материалам рекомендаций американского общества клинической онкологии, март 2017) // Consilium Medicum. 2017. Т. 19, № 6. С. 66-71.
3. Palle C., Bangsboll S., Andreasson B. Cervical intraepithelial neoplasia in pregnancy // Acta Obstet. Gynecol. Scand. 2000. Vol. 79. P. 306-310.
4. Аполихина И.А., Филиппенкова Е.В., Додова Е.Г. и др. Современные возможности организованного скрининга рака шейки матки // Акуш. и гин. 2016. № 9. С. 12-19.
5. Smith L.H., Danialsen B., Allen M.E., Cress R. Cancer associated with obstetric delivery: Results of linkage with the California cancer registry // Am. J. Obstet. Gynecol. 2003. Vol. 189. P. 1128-1135.
6. Mclntyre-Seltman K., Lesnock J.L. Cervical cancer screening in pregnancy // Obstet. Gynecol. Clin. North Am. 2008. Vol. 35. P. 645-658.
7. Ebisch R.M., Siebers A.G., Bosgraaf R.P. et al. Triage of high-risk HPV positive women in cervical cancer screening // Expert Rev. Anticancer Ther. 2016. Vol. 16, N 10. P. 1073-1085.
8. Luttmer R., De Strooper L.M., Steenbergen R.D. et al. Management of high-risk HPV-positive women for detection of cervical (pre)cancer // Expert Rev. Mol. Diagn. 2016. Vol. 16, N 9. P. 961-974.
9. Gasparini G., Bevilacqua P., Pozza F. et al. Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer // Br. J. Cancer. 2008. Vol. 66. P. 970-976.
10. Jonat W., Arnold N. Is the Ki-67 labelling index ready for clinical use? // Ann. Oncol. 2011. Vol. 22. P. 500-502.
11. Kruger K., Stefansson I.M., Collett K. et al. Microvessel proliferation by co-expression of endothelial nestin and Ki-67 is associated with a basal-like phenotype and aggressive features in breast cancer // Breast. 2013. Vol. 22. P. 282-288.
12. Duchrow M., Schluter C., Key G., Kubbutat M. et al. Cell proliferation-associated nuclear antigen defined by antibody Ki-67: a new kind of cell cycle-maintaining proteins // Arch. Immunol. Ther. Exp. (Warsz.). 1995. Vol. 43. P. 117-121.
13. Scholzen T., Gerdes J. The Ki-67 protein: From the known and the unknown // J. Cell. Physiol. 2000. Vol. 182. P. 311-322.
14. Tornesello M.L., Buonaguro L., Giorgi Rossi P., Buonaguro F.M. Viral and cellular biomarkers in the diagnosis of cervical Intraepithelial neoplasia and cancer // Biomed. Res. Int. 2013. Vol. 2013. Article ID 519619.
15. Cordeiro C.N., Gemignani M.L. Gynecologic malignancies in pregnancy: balancing fetal risks with oncologic safety // Obstet. Gynecol. Surv. 2017. Vol. 72, N 3. P. 184-193.
16. Wu Y.M., Wang T., He Y., Song F. et al. Clinical management of cervical intraepithelial neoplasia in pregnant and postpartum women // Arch. Gynecol. Obstet. 2014. Vol. 289. P. 1071-1077.
17. Zappacosta R., Colasante A., Viola P., D'Antuono T. et al. Chromogenic in situ hybridization and p16/Ki67 dual staining on formalin-fixed paraffin-embedded cervical specimens: correlation with HPV-DNA test, E6/E7 mRNA test, and potential clinical apllications // Biomed. Res. Int. 2013. Vol. 2013. Article ID 453606.
18. Carozzi F., Confortini M., Dalla Palma P., Del Mistro A. et al. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial // Lancet Oncol. 2008. Vol. 9. P. 937-945.
19. Kaplan K.J., Dainty L.A., Dolinsky B., Rose G.S. et al. Prognosis and recurrence risk for patients with cervical squamous intraepithelial lesions diagnosed during pregnancy // Cancer. 2004. Vol. 102. P. 228232.
20. Munger K., BasiLe J.R., Duensing S., Eichten A. et aL. BioLogicaL activities and molecular targets of the human papillomavirus E7 oncoprotein // Oncogene. 2001. VoL. 20. P. 7888-7898.
21. KhLeif S.N., DeGregori J., Yee C.L., Otterson G.A. et aL. Inhibition of cycLin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cycLin kinase inhibitor activity // Proc. NatL Acad. Sci. USA. 1996. VoL. 93. P. 4350-4354.
22. von KnebeL Doeberitz M., RittmuLLer C., zur Hausen H., Durst M. Inhibition of tumorigenicity of cervicaL cancer ceLLs in nude mice by HPV E6-E7 anti-sense RNA // Int. J. Cancer. 1992. VoL. 51. P. 831-834.
23. Kong C.S., BaLzer B.L., TroxeLL M.L., Patterson B.K. et aL. p16INK4A immunohistochemistry is superior to HPV in situ hybridization for the detection of high-risk HPV in atypicaL squamous metapLasia // Am. J. Surg. PathoL. 2007. VoL. 31. P. 33-43.
24. WaLts A.E., Bose S. p16, Ki-67 and BD ProExC immunostaining: a practicaL approach for diagnosis of cervicaL intraepitheLiaL neopLasia // Hum. PathoL. 2009. VoL. 40. P. 957-964.
25. Pinto A.P., SchLecht N.F., Woo T.Y., Crum C.P. et aL. Biomarker (ProEx C, p16INK4A, and MiB-1) distinction of high-grade squamous intraepitheLiaL Lesion from its mimics // Mod. PathoL. 2008. VoL. 21. P. 1067-1074.
26. Badr R.E., WaLts A.E., Chung F., Bose S. BD ProEx C: a sensitive and specific marker of HPV-associated squamous Lesions of the cervix // Am. J. Surg. PathoL. 2008. VoL. 32.. P. 899-906.
27. Shi J., Liu H., WiLkerson M., Huang Y. et aL. EvaLuation of p16INK4a, minichromosome maintenance protein 2, DNA topoisomerase II aLpha, ProEX C, and p16INK4a/ProEX C in cervicaL squamous intraepitheLiaL Lesions // Hum. PathoL. 2007. VoL. 38. P. 1335-1344.
28. KLaes R., Friedrich T., Spitkovsky D., Ridder R. et aL. Overexpression of p16(INK4A) as a specific marker for dyspLastic and neopLastic epitheLiaL ceLLs of the cervix uteri // Int. J. Cancer. 2001. VoL. 92. P. 276-284.
29. BenevoLo M., Terrenato I., MottoLese M., Marandino F. et aL. Comparative evaLuation of nm23 and p16 expression as biomarkers of high-risk human papiLLomavirus infection and cervicaL intraepitheLiaL neopLasia 2(+) Lesions of the uterine cervix // HistopathoLogy. 2010. VoL. 57. P. 580-586.
30. Pacchiarotti A., Ferrari F., BeLLardini P., Chini F. et aL. Prognostic vaLue of p16-INK4A protein in women with negative or CIN1 histoLogy resuLt: a foLLow-up study // Int. J. Cancer. 2014. VoL. 134. P. 897-904.
31. Kim K.I., Lee K.H., Kim T.R. et aL. Ki-67 as a predictor of response to neoadjuvant chemotherapy in breast cancer patients // J. Breast Cancer. 2014. VoL. 17, N 1. P. 40-46.
32. Montagna E., Bagnardi V., ViaLe G. et aL. Changes in PgR and Ki-67 in residuaL tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapy // Ann. OncoL. 2015. VoL. 26, N 2. P. 307-313.
33. Kwok T.C., Rakha E.A., Lee A.H. et aL. HistoLogicaL grading of breast cancer on needLe core biopsy: the roLe of immunohistochemicaL assessment of proLiferation // HistopathoLogy. 2010. VoL. 57, N 2. P. 212-219.
34. Sarian L.O., Derchain S.F., Yoshida A., VassaLLo J. et aL. Expression of cycLoxygenase-2 (COX-2) and Ki67 as reLated to disease severity and HPV detection in squamous Lesions of the cervix // GynecoL. OncoL. 2006. VoL. 102. P. 537-541.
35. CaLiL L.N., EdeLweiss M.I., Meurer L., Igansi C.N. et aL. p16 INK4a and Ki67 expression in normal, dyspLastic and neopLastic uterine cervicaL epitheLium and human papiLLomavirus (HPV) infection // PathoL. Res. Pract. 2014. VoL. 210. P. 482-487.
36. SasLow D., SoLomon D., Lawson H., KiLLackey M. et aL. American Cancer Society; American Society for CoLposcopy and CervicaL PathoLogy; American Society for CLinicaL PathoLogy: American Cancer Society, American Society for CoLposcopy and CervicaL PathoLogy, and American Society for CLinicaL PathoLogy screening guideLines for the prevention and earLy detection of cervicaL cancer // Am. J. CLin. PathoL. 2012. VoL. 137. P. 516-542.
37. Fader A.N., ALward E.K., Niederhauser A., Chirico C. et aL. CervicaL dyspLasia in pregnancy: a muLti-institutionaL evaLuation // Am. J. Obstet. GynecoL. 2010. VoL. 203. P. 113.e1-e6.
38. Frega A., Scirpa P., Corosu R., Verrico M. et aL. CLinicaL management and foLLow-up of squamous intraepitheLiaL cervicaL Lesions during pregnancy and postpartum // Anticancer Res. 2007. VoL. 27. P. 2743-2746.
39. Wright T.C., Massad L.S., Dunton C.J., Spitzer M. et aL. 2006 ASCCP-Sponsored Consensus Conference: 2006 consensus guideLines for the management of women with abnormaL cervicaL cancer screening tests // J. Low Genit. Tract. Dis. 2007. VoL. 11. P. 201-222.
40. VLahos G., RodoLakis A., DiakomanoLis E., Stefanidis K. et aL. Conservative management of cervicaL intraepitheLiaL neopLasia (CIN (2-3)) in pregnant women // GynecoL. Obstet. Invest. 2002. VoL. 54. P. 78-81.
41. Ciavattini A., SopracordevoLe F., Di Giuseppe J. et aL. CervicaL intraepitheLiaL neopLasia in pregnancy: Interference of pregnancy status with p16 and Ki-67 protein expression // OncoL. Lett. 2017. VoL. 13, N 1. P. 301-306.
42. Trutnovsky G., KoLovetsiou-Kreiner V., Reich O. p16/Ki-67 duaLstained cytoLogy testing may predict postpartum outcome in patients with abnormaL PapanicoLaou cytoLogy during pregnancy // Acta CytoL. 2014. VoL. 58, N 3. P. 293-296.
43. Kim J., Bagchi I.C., Bagchi M.K. ControL of ovuLation in mice by progesterone receptor-reguLated gene networks // MoL. Hum. Reprod. 2009. VoL. 15. P. 821-828.
References
1. Gorobtsova V.V., KovaLev A.A. CervicaL cancer: the urgency of the probLem, the principLes of treatment. GLavniy vrach Yuga Rossii [Chief Physician of the South of Russia]. 2016; 1 (48): 63-6. (in Russian).
2. Dubrovina S.O. Primary and secondary prevention of cervicaL cancer (based on the recommendations of the American Society of CLinicaL OncoLogy, March 2017). ConsiLium Medicum. 2017; 19 (6): 66-71. (in Russian).
3. PaLLe C., BangsboLL S., Andreasson B. CervicaL intraepitheLiaL neopLasia in pregnancy. Acta Obstet GynecoL Scand. 2000; 79: 306-10.
4. ApoLikhina I.A., FiLippenkova E.V., Dodova Ye.G. Modern possibiLities of organized screening of cervicaL cancer. Obstetrics and gynecoLogy. Akusher-stvo i ginekoLogiya [Obstetrics and GynecoLogy]. 2016; (9): 12-9. (in Russian).
5. Smith L.H., DaniaLsen B., ALLen M.E., Cress R. Cancer associated with obstetric deLivery: ResuLts of Linkage with the CaLifornia cancer registry. Am J Obstet GynecoL 2003; 189: 1128-35.
6. McIntyre-SeLtman K., Lesnock J.L. CervicaL cancer screening in pregnancy. Obstet GynecoL CLin North Am. 2008; 35: 645-58.
7. Ebisch R.M., Siebers A.G., Bosgraaf R.P., et aL. Triage of high-risk HPV positive women in cervicaL cancer screening. Expert Rev Anticancer Ther. 2016; 16 (10): 1073-85.
8. Luttmer R., De Strooper L.M., Steenbergen R.D., et aL. Management of high-risk HPV-positive women for detection of cervicaL (pre)cancer. Expert Rev MoL Diagn. 2016; 16(9): 961-74.
9. Gasparini G., Bevilacqua P., Pozza F., et al. Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer. Br J Cancer. 2008; 66: 970-6.
10. Jonat W., Arnold N. Is the Ki-67 labelling index ready for clinical use? Ann Oncol. 2011; 22: 500-2.
11. Kruger K., Stefansson I.M., Collett K., et al. Microvessel proliferation by co-expression of endothelial nestin and Ki-67 is associated with a basal-like phenotype and aggressive features in breast cancer. Breast. 2013; 22: 282-8.
12. Duchrow M., Schluter C., Key G., Kubbutat M., et al. Cell proliferation-associated nuclear antigen defined by antibody Ki-67: a new kind of cell cycle-maintaining proteins. Arch Immunol Ther Exp (Warsz). 1995; 43: 117-21.
13. Scholzen T., Gerdes J. The Ki-67 protein: From the known and the unknown. J Cell Physiol. 2000; 182: 311-22.
14. Tornesello M.L., Buonaguro L., Giorgi Rossi P., Buonaguro F.M. Viral and cellular biomarkers in the diagnosis of cervical Intraepithelial neoplasia and cancer. Biomed Res Int 2013; 2013: 519619.
15. Cordeiro C.N., Gemignani M.L. Gynecologic malignancies in pregnancy: balancing fetal risks with oncologic safety. Obstet Gynecol Surv. 2017; 72 (3): 184-93.
16. Wu Y.M., Wang T., He Y., Song F., et al. Clinical management of cervical intraepithelial neoplasia in pregnant and postpartum women. Arch Gynecol Obstet. 2014; 289: 1071-7.
17. Zappacosta R., Colasante A., Viola P., D'Antuono T., et al. Chromogenic in situ hybridization and p16/Ki67 dual staining on formalin-fixed paraffin-embedded cervical specimens: correlation with HPV-DNA test, E6/ E7 mRNA test, and potential clinical apllications. Biomed Res Int. 2013; 2013: 453606.
18. Carozzi F., Confortini M., Dalla Palma P., Del Mistro A., et al. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: A nested substudy of the NTCC randomised controlled trial. Lancet Oncol. 2008; 9: 937-45.
19. Kaplan K.J., Dainty L.A., Dolinsky B., Rose G.S., et al. Prognosis and recurrence risk for patients with cervical squamous intraepithelial lesions diagnosed during pregnancy. Cancer. 2004; 102: 228-32.
20. Munger K., Basile J.R., Duensing S., Eichten A., et al. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene. 2001; 20: 7888-98.
21. Khleif S.N., DeGregori J., Yee C.L., Otterson G.A., et al. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci USA. 1996; 93: 4350-4.
22. von Knebel Doeberitz M., Rittmuller C., zur Hausen H., Durst M. Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 anti-sense RNA. Int J Cancer. 1992; 51: 831-4.
23. Kong C.S., Balzer B.L., Troxell M.L., Patterson B.K., et al. p16INK4A immunohistochemistry is superior to HPV in situ hybridization for the detection of high-risk HPV in atypical squamous metaplasia. Am J Surg Pathol. 2007; 31: 33-43.
24. Walts A.E., Bose S. p16, Ki-67 and BD ProExC immunostaining: A practical approach for diagnosis of cervical intraepithelial neoplasia. Hum Pathol. 2009; 40: 957-64.
25. Pinto A.P., Schlecht N.F., Woo T.Y., Crum C.P., et al. Biomarker (ProEx C, p16INK4A, and MiB-1) distinction of high-grade squamous intraepithelial lesion from its mimics. Mod Pathol.2008; 21: 1067-74.
26. Badr R.E., Walts A.E., Chung F., Bose S. BD ProEx C: a sensitive and specific marker of HPV-associated squamous lesions of the cervix. Am J Surg Pathol. 2008; 32: 899-906.
27. Shi J., Liu H., Wilkerson M., Huang Y., et al. Evaluation of p16INK4a, minichromosome maintenance protein 2, DNA topoisome-rase II alpha, ProEX C, and p16INK4a/ProEX C in cervical squamous intraepithelial lesions. Hum Pathol. 2007; 38: 1335-44.
28. Klaes R., Friedrich T., Spitkovsky D., Ridder R., et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer. 2001; 92: 276-84.
29. Benevolo M., Terrenato I., Mottolese M., Marandino F., et al. Comparative evaluation of nm23 and p16 expression as biomarkers of high-risk human papillomavirus infection and cervical intraepithelial neoplasia 2(+) lesions of the uterine cervix. Histopathology. 2010; 57: 580-6.
30. Pacchiarotti A., Ferrari F., Bellardini P., Chini F., et al. Prognostic value of p16-INK4A protein in women with negative or CIN1 histology result: a follow-up study. Int J Cancer. 2014; 134: 897-904.
31. Kim K.I., Lee K.H., Kim T.R., et al. Ki-67 as a predictor of response to neoadjuvant chemotherapy in breast cancer patients. J Breast Cancer. 2014; 17 (1): 40-6.
32. Montagna E., Bagnardi V., Viale G., et al. Changes in PgR and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapy. Ann Oncol. 2015; 26 (2): 307-13.
33. Kwok T.C., Rakha E.A., Lee A.H., et al. Histological grading of breast cancer on needle core biopsy: the role of immunohistochemical assessment of proliferation. Histopathology. 2010; 57 (2): 212-9.
34. Sarian L.O., Derchain S.F., Yoshida A., Vassallo J., et al. Expression of cycloxygenase-2 (COX-2) and Ki67 as related to disease severity and HPV detection in squamous lesions of the cervix. Gynecol Oncol. 2006; 102: 537-41.
35. Calil L.N., Edelweiss M.I., Meurer L., Igansi C.N., et al. p16 INK4a and Ki67 expression in normal, dysplastic and neoplastic uterine cervical epithelium and human papillomavirus (HPV) infection. Pathol Res Pract. 2014; 210: 482-7.
36. Saslow D., Solomon D., Lawson H., Killackey M., et al. American Cancer Society; American Society for Colposcopy and Cervical Pathology; American Society for Clinical Pathology: American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012; 137: 516-42.
37. Fader A.N., Alward E.K., Niederhauser A., Chirico C., et al. Cervical dysplasia in pregnancy: A multi-institutional evaluation. Am J Obstet Gynecol. 2010; 203: 113.e1-6.
38. Frega A., Scirpa P., Corosu R., Verrico M., et al. Clinical management and follow-up of squamous intraepithelial cervical lesions during pregnancy and postpartum. Anticancer Res. 2007; 27: 2743-6.
39. Wright T.C., Massad L.S., Dunton C.J., Spitzer M., et al. 2006 ASCCP-Sponsored Consensus Conference: 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. J Low Genit Tract Dis. 2007; 11: 201-22.
40. Vlahos G., Rodolakis A., Diakomanolis E., Stefanidis K., et al. Conservative management of cervical intraepithelial neoplasia (CIN (2-3)) in pregnant women. Gynecol Obstet Invest. 2002; 54: 78-81.
41. Ciavattini A., Sopracordevole F., Di Giuseppe J., et al. Cervical intraepithelial neoplasia in pregnancy: Interference of pregnancy status with p16 and Ki-67 protein expression. Oncol. Lett. 2017; 13 (1): 301-6.
42. Trutnovsky G., Kolovetsiou-Kreiner V., Reich O. p16/Ki-67 dual-stained cytology testing may predict postpartum outcome in patients with abnormal Papanicolaou cytology during pregnancy. Acta Cytol. 2014; 58 (3): 293-6.
43. Kim J., Bagchi I.C., Bagchi M.K. Control of ovulation in mice by progesterone receptor-regulated gene networks. Mol Hum Reprod. 2009; 15: 821-8.